主要文件

查看所有文档

B7273

苯扎贝特

Name: 苯扎贝特
Brand: SIGMA

≥98%, peroxisome proliferator-activated receptor agonist, solid

别名:

2- [4- [2-（4-氯苯甲酰胺基）苄]苯氧基] -2-甲基丙酸

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₉H₂₀ClNO₄

化学文摘社编号:

41859-67-0

分子量:

361.82

NACRES:

NA.77

PubChem Substance ID:

24891983

UNSPSC Code:

12352200

EC Number:

255-567-9

MDL number:

MFCD00078970

Assay:

≥98%

Form:

solid

Quality level:

200

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

苯扎贝特, ≥98%, solid

Quality Level

200

assay

≥98%

form

solid

solubility

DMF: soluble, deionized water: insoluble, methanol: soluble

originator

Roche

SMILES string

CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O

InChI

1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)

InChI key

IIBYAHWJQTYFKB-UHFFFAOYSA-N

Gene Information

human ... HBA2(3040), PPARA(5465), PPARD(5467), PPARG(5468)
mouse ... Ppara(19013), Ppard(19015), Pparg(19016)

说明

Application

苯扎贝特已被用于：

小鼠标准饲料 (SD) 中的补充剂，用于研究其对糖尿病的影响
评估其对丙型肝炎病毒 (HCV) 组装和分泌的影响
评估其对斑马鱼性腺类固醇生成和精子生成的影响，也用作 HPLC 的标准

Biochem/physiol Actions

苯扎贝特具有抑制 HCV 组装和分泌的能力。它用于治疗血脂异常。

苯扎贝特是过氧化物酶体增殖物激活受体活化剂，用于PPARα、PPARδ和PPARγ。脂蛋白脂酶（LPL）激活剂。

过氧化物酶体增殖物激活受体（PPAR）是类固醇核受体超家族成员之一。苯扎贝特是过氧化物酶体增殖物激活受体活化剂，用于PPARα、PPARδ和PPARγ。脂蛋白脂酶（LPL）激活剂。
PPARgamma激动剂（包括苯扎贝特）在抑制RSV感染期间的炎症反应中具有有益作用，因此在重度RSV感染过程中可能具有临床疗效。

Features and Benefits

该化合物由Roche开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。

这种化合物是基因调控研究的特色产品。点击此处发现更多特色基因调控产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。

Still not finding the right product?

Explore all of our products under 苯扎贝特

pictograms

GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

商品

Discover Bioactive Small Molecules for Gene Regulation

We offer a variety of small molecule research tools, such as transcription factor modulators, inhibitors of chromatin modifying enzymes, and agonists/antagonists for target identification and validation in gene regulation research; a selection of these research tools is shown below.

Square-wave voltammetric determination of bezafibrate in pharmaceutical formulations using a cathodically pretreated boron-doped diamond electrode.

Jorge Armando Ardila et al.

Talanta, 103, 201-206 (2012-12-04)

The determination of bezafibrate (BZF) using square-wave voltammetry (SWV) and a cathodically pretreated boron-doped diamond electrode is proposed. Cyclic voltammetry results showed one irreversible oxidation peak for BZF at 1.20 V (vs. Ag/AgCl (3.0 mol L(-1) KCl)) in a 0.04

Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.

Alexander Constantinides et al.

European journal of internal medicine, 23(7), 633-638 (2012-08-21)

Plasma lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) levels predict incident cardiovascular disease, impacting Lp-PLA(2) as an emerging therapeutic target. We determined Lp-PLA(2) responses to statin and fibrate administration in type 2 diabetes mellitus, and assessed relationships of changes in Lp-PLA(2) with subclinical

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.

Akira Honda et al.

Hepatology (Baltimore, Md.), 57(5), 1931-1941 (2012-08-23)

Bezafibrate is a widely used hypolipidemic agent and is known as a ligand of the peroxisome proliferator-activated receptors (PPARs). Recently this agent has come to be recognized as a potential anticholestatic medicine for the treatment of primary biliary cirrhosis (PBC)

查看所有相关文献

全球贸易项目编号

货号	GTIN
B7273-1G	04061833441688
B7273-25G	04061832953014
B7273-5G	04061833441695